ArticleClinical and experimental nephrology2026
Diagnosis and treatment in adult patients with C3 glomerulopathy in Japan: a real-world survey.
Article in Clinical and experimental nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionC3 glomerulopathy (C3G) is an ultra-rare, complex, under-recognized kidney disease with a challenging diagnosis and no approved treatment. Nephrologists were surveyed to understand the treatment and management of C3G. This study presents the diagnostic challenges and treatment patterns of Japanese patients with C3G.
methodsData from the Adelphi C3G Disease Specific Programme™, a multinational survey of nephrologists treating patients with C3G in 8 countries including Japan, were retrospectively analyzed. Nephrologists completed patient-record forms on patient demographics, diagnosis, clinical characteristics, and treatment approaches.
resultsSixteen nephrologists from Japan responded to the survey for 36 patients with C3G. Mean age at diagnosis and at the time of the survey was 45.4 and 48.6 years, respectively. Common symptoms at diagnosis were proteinuria (100%) and hematuria (83%); 79% of patients had proteinuria of ≥1 g/day, and 3% had an estimated glomerular filtration rate of <30 mL/min/1.73 m
conclusionThis survey analysis explored the current status in diagnosis and management of patients with C3G in Japan. The lack of specific treatments emphasizes the need for novel targeted therapies addressing the root cause of C3G.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.